WO2003083101A1 - Dap kinase crystals, method of screening candidate for drug targeting dap kinase using the same and drug obtained thereby - Google Patents

Dap kinase crystals, method of screening candidate for drug targeting dap kinase using the same and drug obtained thereby Download PDF

Info

Publication number
WO2003083101A1
WO2003083101A1 PCT/JP2003/003806 JP0303806W WO03083101A1 WO 2003083101 A1 WO2003083101 A1 WO 2003083101A1 JP 0303806 W JP0303806 W JP 0303806W WO 03083101 A1 WO03083101 A1 WO 03083101A1
Authority
WO
WIPO (PCT)
Prior art keywords
dap kinase
drug
crystals
dapk
same
Prior art date
Application number
PCT/JP2003/003806
Other languages
French (fr)
Japanese (ja)
Inventor
Arno Paehler
Hiroyuki Shibata
Takeshi Hioki
Kazunori Yamada
Hideo Kubodera
Shinji Sunada
Yoshiki Higuchi
Akira Yamakawa
Original Assignee
Mitsubishi Pharma Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Pharma Corporation filed Critical Mitsubishi Pharma Corporation
Priority to AU2003227255A priority Critical patent/AU2003227255A1/en
Priority to JP2003580537A priority patent/JPWO2003083101A1/en
Publication of WO2003083101A1 publication Critical patent/WO2003083101A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)

Abstract

It is intended to provide crystals of DAP kinase (death-associated protein kinase; hereinafter sometimes referred to as “DAPK”); three-dimensional structure coordinates of DAPK obtained by an X-ray diffraction pattern of the crystals; a computer program containing the three-dimensional structure coordinates; a method of screening a drug targeting DAPK with the use of the three-dimensional structure coordinates; a drug targeting DAPK which is obtained by the method; etc. It is further intended to provide a method of the mass expression of DAPK as a solubilized protein.
PCT/JP2003/003806 2002-03-29 2003-03-27 Dap kinase crystals, method of screening candidate for drug targeting dap kinase using the same and drug obtained thereby WO2003083101A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2003227255A AU2003227255A1 (en) 2002-03-29 2003-03-27 Dap kinase crystals, method of screening candidate for drug targeting dap kinase using the same and drug obtained thereby
JP2003580537A JPWO2003083101A1 (en) 2002-03-29 2003-03-27 Crystal of DAP kinase, method for screening drug candidate molecule targeting DAP kinase using the same, and medicament obtained thereby

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2002097394 2002-03-29
JP2002-97394 2002-03-29
JP2003-51670 2003-02-27
JP2003051670 2003-02-27

Publications (1)

Publication Number Publication Date
WO2003083101A1 true WO2003083101A1 (en) 2003-10-09

Family

ID=28677592

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2003/003806 WO2003083101A1 (en) 2002-03-29 2003-03-27 Dap kinase crystals, method of screening candidate for drug targeting dap kinase using the same and drug obtained thereby

Country Status (3)

Country Link
JP (1) JPWO2003083101A1 (en)
AU (1) AU2003227255A1 (en)
WO (1) WO2003083101A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995010630A1 (en) * 1993-10-12 1995-04-20 Yeda Research And Development Co. Ltd. Tumor suppressor genes, proteins encoded thereby and use of said genes and proteins
WO2000044926A1 (en) * 1999-01-27 2000-08-03 Stratagene High level expression of a heterologous protein having rare codons

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995010630A1 (en) * 1993-10-12 1995-04-20 Yeda Research And Development Co. Ltd. Tumor suppressor genes, proteins encoded thereby and use of said genes and proteins
WO2000044926A1 (en) * 1999-01-27 2000-08-03 Stratagene High level expression of a heterologous protein having rare codons

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
KIM D.Y. ET AL.: "Expression and characterization of the HMG-CoA reductase of the thermophilic archaeon sulfolobus solfataricus", PROTEIN EXPR. PURIF., vol. 17, no. 3, 1999, pages 435 - 442, XP004441593 *
TERESHKO V. ET AL.: "Crystal structures of the catalytic domain of human protein kinase associated with apoptosis and tumor suppression", NAT. STRUCT. BIOL., vol. 8, no. 10, 2001, pages 899 - 907, XP002972103 *
VAN ELDIK L.J. ET AL.: "Structure and enzymology of a death-associated protein kinase", TRENDS PHARMACOL. SCI., vol. 23, no. 7, July 2002 (2002-07-01), pages 302 - 304, XP004370507 *
VELENTZA A.V. ET AL.: "A protein kinase associated with apoptosis and tumor suppression: structure, activity and discovery of peptide substrates", J. BIOL. CHEM., vol. 276, no. 42, 2001, pages 38956 - 38965, XP002972105 *
VELENTZA A.V. ET AL.: "Structure, activity, regulation and inhibitor discovery for a protein kinase associated with apoptosis and neuronal death", PHARMACOL. THER., vol. 93, no. 2-3, February 2002 (2002-02-01) - March 2002 (2002-03-01), pages 217 - 224, XP002972104 *

Also Published As

Publication number Publication date
JPWO2003083101A1 (en) 2005-08-04
AU2003227255A1 (en) 2003-10-13

Similar Documents

Publication Publication Date Title
MY149803A (en) Markup based extensibility for user interfaces
BRPI0411112A (en) heterologous fusion protein, polynucleotide, vector, host cell, process for producing a heterologous fusion protein, method for treating a patient, and use of heterologous fusion protein
ATE396731T1 (en) THIAZOLES FOR USE AS INHIBITORS OF PROTEIN KINASES
WO2004041160A3 (en) Methods and animal model for analyzing age-related macular degeneration
ATE433973T1 (en) AZOLYLAMINOAZINES AS INHIBITORS OF PROTEIN KINASES
CY1114866T1 (en) METHOD FOR PRODUCING AMINOCROTONYL COMPOUNDS
ATE431111T1 (en) DEVICE FOR TOTAL KNEE CONSTRUCTION
EP1053255A4 (en) THREE-DIMENSIONAL STRUCTURES AND MODELS OF Fc RECEPTORS AND USES THEREOF
BRPI0410078A (en) use of glutaminyl and glutamate cyclase effectors
ATE466580T1 (en) AZOLYLAMINOAZINE AS PROTEIN KINASE INHIBITORS
TW200517960A (en) System incorporating physics processing unit
WO2007011878A3 (en) Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists
WO2005008487A3 (en) Method and apparatus for partitioning code in program code conversion
HK1075663A1 (en) Novel heteroaryl-substituted acetone derivatives as inhibitors of phospholipase a sb 2 /sb
DE602007001467D1 (en) Therapeutic preparation of high purity FVIIa and method for its recovery
WO2007071442A3 (en) Inhibitors of ccr9 activity
WO2003083101A1 (en) Dap kinase crystals, method of screening candidate for drug targeting dap kinase using the same and drug obtained thereby
BR0100164A (en) Pharmacophore models, screening methods, and identification of the cytochrome p-450 inhibitory potency of neurokinin-1 receptor antagonists
AU2003285590A1 (en) Systems, methods, and computer program products to modify the graphical display of data entities and relational database structures
WO2001051651A3 (en) High expression and production of high-specific activity recombinant s-adenosyl homocysteinase (sahh) and improved assays for s-adenosylmethionine (sam)
WO2003065978A3 (en) Crystals and structures of a flavin mononucleotide binding protein (fmnbp)
EA200601030A1 (en) 7α, 17α-SUBSTITUTED 11β-HALOGENOSTEROIDS, METHODS FOR THEIR RECEPTION, APPLICATION AND PHARMACEUTICAL PREPARATION ON THEIR BASIS
WO2004084800A3 (en) A3 receptor-mediated cardioprotective proteins and therapeutic and diagnostic methods of use
BRPI0411248A (en) method for producing a polypeptide
ATE405641T1 (en) DDR2 PROTEIN WITH ACTIVATED KINASE ACTIVITY AND METHOD FOR THE PRODUCTION THEREOF

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003580537

Country of ref document: JP

122 Ep: pct application non-entry in european phase